Corcept Therapeutics Announces Third Quarter Financial Results, Positive Results From Phase 3 GRADIENT Trial in Patients With Cushing’s Syndrome and Provides Corporate Update
Corcept Therapeutics Incorporated (CORT)
Last corcept therapeutics incorporated earnings: 2/20 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
corcept.com/investors
Company Research
Source: Business Wire
Revenue of $182.5 million, a 48 percent increase over the same period in 2023Increase in 2024 revenue guidance to $675 – $700 million, from $640 – $670 millionNet income per common share of $0.41 (diluted), compared to $0.28 in third quarter 2023Cash and investments of $547.6 million as of September 30, 2024Results from Phase 3 GRADIENT trial support findings from pivotal Phase 3 GRACE study; new drug application (NDA) of relacorilant to be submitted this quarter REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter ended September 30, 2024.Financial Results“In the third quarter, we added more Korlym® prescribers and more patients received Korlym treatment than ever before,” said Joseph K. Belanof
Show less
Read more
Impact Snapshot
Event Time:
CORT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CORT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CORT alerts
High impacting Corcept Therapeutics Incorporated news events
Weekly update
A roundup of the hottest topics
CORT
News
- Corcept Shares Rise More Than 60% in Three Months: Here's Why [Yahoo! Finance]Yahoo! Finance
- Wall Street Analysts Think Corcept (CORT) Could Surge 37.91%: Read This Before Placing a Bet [Yahoo! Finance]Yahoo! Finance
- Corcept (CORT) is on the Move, Here's Why the Trend Could be Sustainable [Yahoo! Finance]Yahoo! Finance
- 5 Small Drug Stocks to Buy as Trump Gets Re-Elected [Yahoo! Finance]Yahoo! Finance
- Corcept Therapeutics Incorporated (CORT) Soars to 52-Week High, Time to Cash Out? [Yahoo! Finance]Yahoo! Finance
CORT
Earnings
- 10/30/24 - Beat
CORT
Sec Filings
- 11/22/24 - Form 144
- 11/22/24 - Form 144
- 11/13/24 - Form 4
- CORT's page on the SEC website